145 samples were analysed (58 non-PDAC controls, including 18 healthy controls, 25 high-risk controls, 19 patients with non-tumoral pancreatic diseases and 87 patients with PDAC), and PGLYRP1 levels were found to be significantly higher in patients with PDAC (figure 8M, online supplemental figure S8E), suggesting that PGLYRP1 could be a useful biomarker in differential PDAC diagnosis. Here, PGLYRP1 is linked to neoplasm.